H.C. Wainwright upgraded Replimune (REPL) to Buy from Neutral with a $12 price target after the company resubmitted the biologics license application for RP1 plus Opdivo for the treatment of adult patients with advanced melanoma who have previously received an anti-PD1 containing regimen. The firm increased its probability of approval of RP1 plus Opdivo in anti-PD1 failed melanoma patients to 85% from 50%. The FDA indicated that this resubmission is considered a comprehensive response to the complete response letter received in July, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Genelux price target raised to $20 from $10 at Maxim
- Cautious Outlook on Replimune Group Amid FDA Uncertainties and Potential Risks
- Piper upgrades Replimune to Overweight on ‘very pleasant surprise’
- Replimune upgraded to Overweight from Neutral at Piper Sandler
- Replimune Group’s FDA Resubmission for RP1 Accepted